I-MAB (IMAB) Earnings Date & Reports

A.I. Advisor

published Earnings

IMAB is expected to report earnings to fall 41.76% to -12 cents per share on November 29

Q3'23

Est.

$-0.13

Q1'24

Est.

$-0.22

Q4'23

Beat

by $0.36

Q2'23

Beat

by $0.75

Q1'23

Beat

by $0.14

The last earnings report on May 29 showed earnings per share of -21 cents, meeting the estimate of -21 cents. With 418.13K shares outstanding, the current market capitalization sits at 89.21M.

View a ticker or compare two or three

Compare

IMAB

Setup

Buy or SellView

Daily Signalchanged days ago

Gain/Loss if shorted

View Trends For IMAB
(Try 14 days for $1 only)

Ad is loading...

A.I.Advisor

published price charts

A.I. Advisor

published General Information

General Information

a clinical stage biopharmaceutical company, which engages in developing and commercialization of differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders.

Industry Biotechnology

Profile

Fundamentals

Details

Industry

N/A

Address

555 West Haiyang Road

Phone

+86 2160578000

Employees

318

Web

https://www.i-mabbiopharma.com